Chromocell Therapeutics Corporation (CHRO) — Financial Flexibility Index
Chromocell Therapeutics Corporation (CHRO) has a Financial Flexibility Index of -0.06x as of June 2025. Free cash flow of $-447.14K (operating CF $-447.14K minus capex $0.00) represents 0% of total liabilities ($7.32 Million). Also explore Chromocell Therapeutics Corporation net asset momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Chromocell Therapeutics Corporation Financial Flexibility Index (2020–2024)
Historical Financial Flexibility Index trend for Chromocell Therapeutics Corporation across 9 annual periods. See Chromocell Therapeutics Corporation net asset quality index to measure how much of total assets are equity-financed.
Annual Financial Flexibility Index for Chromocell Therapeutics Corporation (2020–2024)
Year-by-year free cash flow to debt coverage for Chromocell Therapeutics Corporation. For the full company profile including market capitalisation, see CHRO market cap overview.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.42x | $-5.79 Million | $-5.79 Million | $4.08 Million | ▼ -845.9% |
| 2023 | -0.15x | $-981.03K | $-981.03K | $6.54 Million | ▲ +0.0% |
| 2023 | -0.15x | $-981.03K | $-981.03K | $6.54 Million | ▲ +64.0% |
| 2022 | -0.42x | $-1.57 Million | $-1.57 Million | $3.76 Million | ▲ +0.0% |
| 2022 | -0.42x | $-1.57 Million | $-1.57 Million | $3.76 Million | ▲ +3.8% |
| 2021 | -0.43x | $-1.59 Million | $-1.59 Million | $3.68 Million | ▲ +0.0% |
| 2021 | -0.43x | $-1.59 Million | $-1.59 Million | $3.68 Million | ▲ +56.4% |
| 2020 | -0.99x | $-3.63 Million | $-3.63 Million | $3.65 Million | ▲ +0.0% |
| 2020 | -0.99x | $-3.63 Million | $-3.63 Million | $3.65 Million | — |